Download PDF
Der Nuklearmediziner 2003; 26(4): 259-268
DOI: 10.1055/s-2003-44822
Multimodale Bildgebung/CME-Beitrag

© Georg Thieme Verlag Stuttgart · New York

Integrierte Koinzidenzbildgebung bei Bronchialkarzinomen

Integrated Imaging Approach in Patients Suffering from Bronchial CarcinomaR. A. Schmid1
  • 1Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München - Innenstadt
Further Information

Publication History

Publication Date:
19 December 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Aufgrund des meist regelhaft erhöhten Glukosestoffwechsels eignet sich das Bronchialkarzinom und seine Metastasen gut für die Darstellung durch die Positronen-Emissions-Tomographie mit [ F-18]Fluor-Deoxy-Glukose. Es ist eine der am ehesten besten untersuchten Indikationen an dezidierten Geräten. Der Stellenwert der Koinzidenzbildgebung bei dieser Fragestellung wird anhand eigener Daten und einer Literaturübersicht beleuchtet, ein Hauptaugenmerk liegt auf den Möglichkeiten und Grenzen der Methode im Vergleich zu den Modalitäten des konventionellen Stagings.

Abstract

The high utilisation of glucose by most types of bronchial carcinoma and its metastases makes imaging with of positron emission tomography using [F-18]fluoro-deoxy-glucose feasible. Lung cancer is one of the best proved indications of this methods for dedicated scanners. The significance of the coincidence technique (hybrid PET) is highlighted by own data and a review of literature, the possibilities and limitations of the method in comparison to the modalities of the conventional staging are the main focus of the paper.

Schlüsselwörter

Bronchialkarzinom - Koinzidenzbildgebung - FDG - Staging

Key words

Bronchial carcinoma - coincidence imaging - FDG - staging

Literatur

  • 1 Ak I, Blokland J A, Pauwels E K, Stokkel M P. The clinical value of 18F-FDG detection with a dual-head coincidence camera: a review.  Eur J Nucl Med. 2001;  28 763-778
    CrossrefPubMedGoogle Scholar
  • 2 Al-Sugair A, Coleman R E. Applications of PET in lung cancer.  Semin Nucl Med. 1998;  28 303-319
    PubMedGoogle Scholar
  • 3 Becker N, Muscat J E, Wynder E L. Cancer mortality in the United States and Germany.  J Cancer Res Clin Oncol. 2001;  127 293-300
    CrossrefPubMedGoogle Scholar
  • 4 Boren E L, Delbeke D, Patton J A, Sandler M P. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies.  Eur J Nucl Med. 1999;  26 379-387
    CrossrefPubMedGoogle Scholar
  • 5 Bury T, Corhay J L, Duysinx B, Daenen F, Ghaye B, Barthelemy N, Rigo P, Bartsch P. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.  Eur Respir J. 1999;  14 1376-1380
    PubMedGoogle Scholar
  • 6 Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach K W, Schicha H. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.  Eur J Nucl Med. 2000;  27 1598-1609
    CrossrefPubMedGoogle Scholar
  • 7 Drane W E, Abbott F D, Nicole M W, Mastin S T, Kuperus J H. Technology for FDG SPECT with a relatively inexpensive gamma camera. Work in progress.  Radiology. 1994;  191 461-465
    PubMedGoogle Scholar
  • 8 Dresel S, Schwenzer K, Brinkbaumer K, Schmid R, Szeimies U, Popperl G, Hahn K. [[F-18]FDG imaging of head and neck tumors: comparison of hybrid PET, dedicated PET and CT].  Nuklearmedizin. 2001;  40 172-178
    PubMedGoogle Scholar
  • 9 Erasmus J J, McAdams H P, Rossi S E, Goodman P C, Coleman R E, Patz E F. FDG PET of pleural effusions in patients with non-small cell lung cancer.  AJR Am J Roentgenol. 2000;  175 245-249
    PubMedGoogle Scholar
  • 10 Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske S N. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).  Thorax. 1997;  52 438-441
    PubMedGoogle Scholar
  • 11 Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch C M. [Metaanalysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose].  Pneumologie. 2001;  55 367-377
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Jarritt P H, Acton P D. PET imaging using gamma camera systems: a review.  Nucl Med Commun. 1996;  17 758-766
    PubMedGoogle Scholar
  • 13 Leonard C T, Whyte R I, Lillington G A. Primary non-small-cell lung cancer: determining the suitability of the patient and tumor for resection.  Curr Opin Pulm Med. 2000;  6 391-395
    CrossrefPubMedGoogle Scholar
  • 14 Lewellen T K, Miyaoka R S, Swan W L. PET imaging using dual-headed gamma cameras: an update.  Nucl Med Commun. 1999;  20 5-12
    PubMedGoogle Scholar
  • 15 Lottes G, Schober O. [Costs of F-18-FDG PET with a satellite concept: update].  Nuklearmedizin. 2000;  39 72-76
    PubMedGoogle Scholar
  • 16 Mac Manus M P, Hicks R J, Matthews J P, Hogg A, McKenzie A F, Wirth A, Ware R E, Ball D L. High rate of detection of unsuspected distant metastases by PET in apparent Stage III non-small-cell lung cancer: implications for radical radiation therapy.  Int J Radiat Oncol Biol Phys. 2001;  50 287-293
    CrossrefPubMedGoogle Scholar
  • 17 Macfarlane D J, Cotton L, Ackermann R J, Minn H, Ficaro E P, Shreve P D, Wahl R L. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.  Radiology. 1995;  194 425-429
    PubMedGoogle Scholar
  • 18 Marom E M, McAdams H P, Erasmus J J, Goodman P C, Culhane D K, Coleman R E, Herndon J E, Patz EF J r. Staging non-small cell lung cancer with whole-body PET.  Radiology. 1999;  212 803-809
    CrossrefPubMedGoogle Scholar
  • 19 Martin W H, Delbeke D, Patton J A, Hendrix B, Weinfeld Z, Ohana I, Kessler R M, Sandler M P. FDG-SPECT: correlation with FDG-PET.  J Nucl Med. 1995;  36 988-995
    PubMedGoogle Scholar
  • 20 McLoud T C, Bourgouin P M, Greenberg R W, Kosiuk J P, Templeton P A, Shepard J A, Moore E H, Wain J C, Mathisen D J, Grillo H C. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.  Radiology. 1992;  182 319-323
    CrossrefPubMedGoogle Scholar
  • 21 Mountain C F. The international system for staging lung cancer.  Semin Surg Oncol. 2000;  18 106-115
    CrossrefPubMedGoogle Scholar
  • 22 Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Yasuda S, Shohtsu A. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy.  Nucl Med Commun. 2001;  22 875-879
    CrossrefPubMedGoogle Scholar
  • 23 Park B J, Louie O, Altorki N. Staging and the surgical management of lung cancer.  Radiol Clin North Am. 2000;  38 545-561
    CrossrefPubMedGoogle Scholar
  • 24 Pieterman R M, van Putten J W, Meuzelaar J J, Mooyaart E L, Vaalburg W, Koeter G H, Fidler V, Pruim J, Groen H J. Preoperative staging of non-small-cell lung cancer with positron-emission tomography.  N Engl J Med. 2000;  343 254-261
    CrossrefPubMedGoogle Scholar
  • 25 Roman M R, Rossleigh M A, Angelides S, Walker B M, Dixon J. Staging and managing lung tumors using F-18 FDG coincidence detection.  Clin Nucl Med. 2001;  26 383-388
    CrossrefPubMedGoogle Scholar
  • 26 Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, Murayama S, Ishida T, Sugio K, Masuda K. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.  Eur J Nucl Med. 1996;  23 741-747
    PubMedGoogle Scholar
  • 27 Schmid R A, Hautmann H, Poellinger B, Kellner W, Moisseev A, Brinkbaeumer K, Weiss M, Hahn K, Dresel S. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).  Nucl Med Commun. 2003;  24 37-45
    PubMedGoogle Scholar
  • 28 Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, Henke M, Moser E, Nitzsche E. FDG-PET imaging for the staging and follow-up of small cell lung cancer.  Eur J Nucl Med. 2001;  28 483-488
    CrossrefPubMedGoogle Scholar
  • 29 Scott W J, Shepherd J, Gambhir S S. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.  Ann Thorac Surg. 1998;  66 1876-1883
    CrossrefPubMedGoogle Scholar
  • 30 Shreve P D, Steventon R S, Deters E C, Kison P V, Groß M D, Wahl R L. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner.  Radiology. 1998;  207 431-437
    CrossrefPubMedGoogle Scholar
  • 31 Slosman D O, Spiliopoulos A, Couson F, Nicod L, Louis O, Lemoine R, Donath A, Junod A F. Satellite PET and lung cancer: a prospective study in surgical patients.  Nucl Med Commun. 1993;  14 955-961
    PubMedGoogle Scholar
  • 32 Som P, Atkins H L, Bandoypadhyay D, Fowler J S, MacGregor R R, Matsui K, Oster Z H, Sacker D F, Shiue C Y, Turner H, Wan C N, Wolf A P, Zabinski S V. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection.  J Nucl Med. 1980;  21 670-675
    PubMedGoogle Scholar
  • 33 Stevens H, Bakker P F, Schlosser N J, van Rijk P P, de Klerk J M. Use of a dual-head coincidence camera and 18F-FDG for detection and nodal staging of non-small cell lung cancer: accuracy as determined by 2 independent observers.  J Nucl Med. 2003;  44(3) 336-340
    PubMedGoogle Scholar
  • 34 Stokkel M P, Bakker P F, Heine R, Schlosser N J, Lammers J W, Van Rijk P P. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer.  Nucl Med Commun. 1999;  20 1001-1007
    PubMedGoogle Scholar
  • 35 Tatsumi M, Yutani K, Watanabe Y, Miyoshi S, Tomiyama N, Johkoh T, Kusuoka H, Nakamura H, Nishimura T. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET.  J Nucl Med. 1999;  40 566-573
    PubMedGoogle Scholar
  • 36 Vansteenkiste J F, Stroobants S G, De Leyn P R, Dupont P J, Bogaert J, Maes A, Deneffe G J, Nackaerts K L, Verschakelen J A, Lerut T E, Mortelmans L A, Demedts M G. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.  J Clin Oncol. 1998;  16 2142-2149
    PubMedGoogle Scholar
  • 37 Vesselle H, Schmidt R A, Pugsley J M, Li M, Kohlmyer S G, Vallires E, Wood D E. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.  Clin Cancer Res. 2000;  6 3837-3844
    PubMedGoogle Scholar
  • 38 Wahl R L, Hutchins G D, Buchsbaum D J, Liebert M, Grossman H B, Fisher S. 18 F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography.  Cancer. 1991;  67 1544-1550
    PubMedGoogle Scholar
  • 39 Wahl R L, Quint L E, Greenough R L, Meyer C R, White R I, Orringer M B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.  Radiology. 1994;  191 371-377
    PubMedGoogle Scholar
  • 40 Weber W, Young C, Abdel-Dayem H M, Sfakianakis G, Weir G J, Swaney C M, Gates M, Stokkel M P, Parker A, Hines H, Khanvali B, Liebig J R, Leung A N, Sollitto R, Caputo G, Wagner H N, Jr. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras.  J Nucl Med. 1999;  40 574-578
    PubMedGoogle Scholar
  • 41 Weber W A, Neverve J, Sklarek J, Ziegler S I, Bartenstein P, King B, Treumann T, Enterrottacher A, Krapf M, Haussinger K E, Lichte H, Prauer H W, Thetter O, Schwaiger M. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system.  Eur J Nucl Med. 1999;  26 388-395
    CrossrefPubMedGoogle Scholar

Dr. med. R. A. Schmid

Klinik und Poliklinik für Nuklearmedizin

Klinikum der Universität München -Innenstadt

Ziemssenstr. 1

80336 München

Phone: +49-(0)89/51 60-24 23

Fax: +49-(0)89/51 60-45 55

Email: rupert.schmid@nuk.med.uni-muenchen.de

      >